Skip to main content
All lobbying filings

FRESENIUS KABI USA LLC

Lobbying for FRESENIUS KABI USA LLC

 Filing 3rd Quarter - Amendment
3rd Quarter (July 1 - Sep 30) 2025 · Illinois · House · Senate · $340,000.00 expenses · posted Nov 25, 2025

Official filing document

 Bills named in this filing 16
 Lobbying activity 6
Trade (domestic/foreign)

Drug Shortages Domestic Manufacturing Tariffs

Medicare/Medicaid

Drug Shortages and Medicaid ERISA Fiduciary Duty IRA Reform

Health Issues

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act S. 1414/H.R._: Expedited Access to Biosimilars Act S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 1041: Affordable Prescriptions for Patients Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 43: Skinny Labels, Big Savings Act S. 1097/H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 HR 4317: PBM Reform Act of 2025 HR 2214: DRUG Act S. 1553/H.R. 3160: PREVAIL Act S. 2305: Biosimilar Red Tape Elimination Act S. 2658: Medication Affordability and Patient Integrity Act ERISA Fiduciary Duty PTAB Discretionary Denials IRA Reform Human Factor Studies Interchangeability Biosimilar User Fee Act (BsUFA) Drug Shortages Domestic Manufacturing

Manufacturing

Domestic Manufacturing

Budget/Appropriations

Domestic Manufacturing Tariffs

Copyright/Patent/Trademark

PTAB Discretionary Denials

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem